Circulating Tumor Cells in Prostate Cancer
AbstractCirculating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual patient’s tumor. In prostate cancer, CTC enumeration has been extensively studied and validated as a prognostic tool and has received FDA clearance for use in monitoring advanced disease. More recently, CTC analysis has been shifting from enumeration to more sophisticated molecular characterization of captured cells, which serve as a “liquid biopsy” of the tumor, reflecting molecular changes in an individual’s malignancy over time. Here we will review the main CTC studies in advanced and localized prostate cancer, highlighting the important gains as well as the challenges posed by various approaches, and their implications for advancing prostate cancer management. View Full-Text
Share & Cite This Article
Hu, B.; Rochefort, H.; Goldkorn, A. Circulating Tumor Cells in Prostate Cancer. Cancers 2013, 5, 1676-1690.
Hu B, Rochefort H, Goldkorn A. Circulating Tumor Cells in Prostate Cancer. Cancers. 2013; 5(4):1676-1690.Chicago/Turabian Style
Hu, Brian; Rochefort, Holly; Goldkorn, Amir. 2013. "Circulating Tumor Cells in Prostate Cancer." Cancers 5, no. 4: 1676-1690.